AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 31 min read$UTHR

MAHON PAUL A sold $4.0M of UTHR

MAHON PAUL A (EVP & GENERAL COUNSEL) sold 8,300 shares of UNITED THERAPEUTICS Corp (UTHR) at an average of $482.03 ($478.93–$490.88, $4.00M total) across 11 trades on 2026-09-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · MAHON PAUL A
Published Sep 3, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 4, 2026, 7:11 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$UTHR
Bearish
medium confidence
Mentioned
$UTHR
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$UTHRBearishLow
01

Why it matters

Direct insider sale may influence short‑term price dynamics.

02

Market read

Routine insider sale with modest size; limited trading relevance.

03

What to watch

Potential upcoming corporate actions or financing needs not disclosed.

Relevance 5/10Novelty 4/10Timing: same‑day filing

Background

Form 4 filing reports insider transaction for United Therapeutics (UTHR).

Company-level read

Ticker impact

$UTHRBearishMedium confidence
Context

EVP & General Counsel Paul Mahon sold 8,300 shares for $4.0M via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 1‑2% as market digests sale.

Evidence & confidence

Sale size is modest but disclosed via Form 4, indicating a direct insider divestment.

Market effects

Sector

Limited impact on biotech sector; typical insider sale.

Regional

Negligible effect on broader market.

Global

None

Counterpoint

What could challenge this read

Sale could be routine portfolio rebalancing, not a bearish signal.

Key entities

  • company
    United Therapeutics Corp

    Biopharma company listed on NYSE under ticker UTHR.

  • insider
    Paul Mahon

    EVP & General Counsel of United Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

UTHR insider trading history →

Related articles

OCT 8
$UTHRMed

UTHR Maintained by RBC Capital -- Price Target Raised to $708

RBC Capital maintained an 'Outperform' rating for United Therapeutics (UTHR) and raised its price target from $677 to $708, citing confidence in the company's performance. GuruFocus estimates UTHR is 24% overvalued with a GF Value of $429.35, while the stock trades at $532.19. The company has a GF Score of 84/100, strong financial health, and a P/E ratio of 19.04x.

gurufocus.com1 min